Genentech, a biotechnology company and member of the Roche Group, announced on May 12, 2025, that it will invest more than $700 million in a new, state-of-the-art drug manufacturing facility in Holly Springs, NC, Genentech’s first facility to be built on the East Coast of the United States. The facility is intended to support Roche and Genentech’s portfolio of next-generation obesity medicines. Source: Pharm Tech 14/5/2025